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Kidney International (2019) 95, 1027–1036I n patients with chronic kidney disease (CKD), the optimalblood pressure (BP) for minimizing the risk of CKDprogression and systemic complications, particularly car-
diovascular events, is unclear. In 2012, Kidney Disease:
Improving Global Outcomes (KDIGO) published a clinical
practice guideline on the management of BP in nondialysis
CKD.1 Since then, new data from clinical trials, such as SPRINT
(Systolic Blood Pressure Intervention Trial),2 HALT-PKD (Halt
Progression of Polycystic Kidney Disease),3 and SPS3 (Secondary
Prevention of Small Subcortical Strokes),4 have expanded the
evidence base. To examine how the new evidence may influence
guideline updates, KDIGO convened a multidisciplinary Con-
troversies Conference titled Blood Pressure in CKD in Edinburgh,
Scotland in September 2017. Here, we summarize the points of
consensus and controversy and identify knowledge gaps and
research priorities. The conference agenda, discussion questions,
and plenary session presentations are available at http://kdigo.
org/conferences/controversies-conference-on-blood-pressure.
BLOOD PRESSURE MEASUREMENT
A major emphasis during the conference was on BP measure-
ment methods. BP can differ widely depending on measurement
setting (e.g., office or home) and the type of device used (e.g.,
manual or oscillometric sphygmomanometer).5,6 Proper prep-
aration prior to BP measurement is important (Table 1). Con-
ference discussions focused primarily on the following 3 types of
office-based BP measurements: (i) routine, or casual, office,
which is conducted without following the recommended pre-
paratory processes outlined in Table 1; (ii) standardized office,1027
Table 1 | Preparations for blood pressure measurement
Office or home7–9
 No talking or use of smartphone during the procedure
 No exercise, nicotine, or caffeine for at least 30 minutes prior to
measurement
 Remove clothing covering location of cuff
 Seated comfortably with legs uncrossed and back and arm sup-
ported for at least 5 minutes prior to measurement
 Verify cuff size is correct
 Middle of the cuff should be placed at the level of the right atrium
Automatic oscillometric measurements10,11
 Average of 2–5 measurements at intervals of 1–2 minutes
Normal office BP
High home or
ambulatory BP
High office BP
High home or
ambulatory BP
Masked
hypertension
Sustained
hypertension
Normal office BP
Normal home or
ambulatory BP
High office BP
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Figure 1 | Classification of patients based on the comparison of
office blood pressure (BP) with home or ambulatory BP levels
in untreated individuals. Large randomized trials with hard
clinical outcomes have primarily targeted office BP values;
therefore, clinical benefits of targeting home or ambulatory BP
values are still unclear. Modified from Parati G, Ochoa JE, Bilo G,
et al. Hypertension in chronic kidney disease part 1: out-of-office
blood pressure monitoring: methods, thresholds, and patterns.
Hypertension. 2016;67:1093–1101. Available at: https://www.
ahajournals.org/doi/full/10.1161/HYPERTENSIONAHA.115.06895.
Accessed February 22, 2019.17 Copyright ª 2016 American Heart
Association, Inc.
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manual technique; and (iii) automated oscillometric office,
which includes a 5-minute rest followed by a series of 2 to 3 BP
measurements that are averaged, as described, for example, in
the SPRINT protocol.12 Two types of out-of-office BP mea-
surements were discussed: (i) home automated oscillometric,
and (ii) 24-hour ambulatory. Pulse wave velocity and central
aortic BP measurements were felt to be outside the scope of the
conference. Non-cuff-based BP measurements are not suffi-
ciently validated to guide practice13 and were not discussed.
Comparisons of different types of BP measurements
Casual office BP is generally 5–10 mm Hg higher than both
standardized office and automated oscillometric office BP,14,15
whereas standardized office BP measurements are generally
similar to those of automated oscillometric office BP.14 Casual
office BP is often higher than awake ambulatory BP; in
contrast, standardized office BP may be lower than awake
ambulatory BP.14 In a subset of participants in the intensive
treatment arm of the SPRINT study, mean automated office
systolic blood pressure (SBP) was 119 mm Hg, whereas mean
awake ambulatory SBP was 126 mm Hg.16 The differences in
BP obtained using different types of measurements in CKD
appear similar to those in the general population, but the
available data are limited.6 The differences between methods
as discussed are population means; in the individuals, those
differences may vary drastically. Therefore, establishing con-
version factors to translate a casual BP value into a stan-
dardized BP value is difficult.
Out-of-office BP measurements
Out-of-office BPmeasurement is required to diagnose white-coat
hypertension (elevated office BPwith controlled out-of-office BP)
andmasked hypertension (controlled office BPwith elevated out-
of-office BP; Figure 1). The prevalence of white-coat hypertension
in patients with CKD from several countries ranges from 2% to
41%,5,18–24 and the prevalence of masked hypertension ranges
from 6% to 51%.5,18,19,21–25 Ambulatory BP provides important
information on nocturnal BP. Patients with CKD are more likely
to have an absence or even a reversal of normal nocturnal dip-
ping, with prevalence ranging from 14% to 75%,18,20-22,26–34
which appears to increase with decreasing kidney function.31
In CKD, out-of-office BP may better predict kidney disease
progression and cardiovascular events than office1028BP.18,20,23,24,27,35–50 Nocturnal BP can be treated specifically
but whether this strategy improves clinical outcomes is un-
clear. In an 8-week, uncontrolled study of 32 nondipping
patients with CKD, shifting 1 antihypertensive drug from
morning to evening restored normal nocturnal dipping in
88% of patients.51 However, this study has yet to be replicated
in a larger cohort with longer follow-up.
No adequately-powered randomized controlled trials (RCTs)
of BP control on clinical outcomes have targeted ambulatory or
home BP in the CKD or general adult population. The sample
size needed and the complexity of such a trial52 raise questions
about its feasibility. In addition, in many regions of the world,
home BP or ambulatory BP monitoring are impractical.
Other BP variabilities
Orthostatic hypotension is usually defined as a decrease in
SBP of at least 20 mm Hg or a decrease in diastolic BP (DBP)
of at least 10 mm Hg within 3 minutes of standing up.53
Orthostatic hypertension is usually defined as a rise in SBP
of at least 20 mm Hg when standing. Estimates based on
SPRINT study data indicate that among older, hypertensive
patients, 5% have orthostatic hypotension and 5% have
orthostatic hypertension.54 Both groups carry an increased
risk of cardiovascular events, as evidenced by multiple cohort
studies.55–57Kidney International (2019) 95, 1027–1036
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term (day-to-day), or longer term (visit-to-visit variability,
VVV). More advanced CKD is associated with higher VVV of
SBP,58 and higher VVV in CKD is associated with adverse car-
diovascular outcomes, adverse renal outcomes, and death. In a
study of 114,900 patients with CKD,58 higher VVV of SBP, in-
dependent of absolute levels of SBP, was associated with higher
rates of heart failure, hemorrhagic stroke, and death. Despite the
prognostic information provided by VVV of SBP, conference
participants felt that its use in the clinical setting or as a target of
therapy remains unclear.
Conclusions and ongoing controversies in BP measurement
Conference participants suggested that the future guideline
work group should explicitly state which BP measurements
should be used to diagnose and manage BP in CKD. Stan-
dardized office BP measurement is rarely performed in clin-
ical practice.7 Given that casual BP tends to provide higher
values than other techniques, but more standardized tech-
niques are often used in RCTs targeting BP, conference par-
ticipants urged the future guideline work group to consider
whether office BP should be measured using an automated
oscillometric device with the appropriate preparations, as
outlined as Table 1.
Conference participants also encouraged exploration of the
evidence on out-of-office BP measurements in conjunction
with office BP measurements in an updated guideline. More
data are also needed regarding whether abnormal diurnal BP
patterns can be restored in patients with CKD, and whether
this strategy would improve clinical outcomes.
MANAGING BLOOD PRESSURE IN CKD PATIENTS WITH AND
WITHOUT DIABETES
Salt intake
Lifestyle, including diet, is an integral component of BP man-
agement. Conference participants indicated that Recommenda-
tion 2.3.2 on salt intake (Chapter 2 of the 2012 KDIGO BP
Guideline1) should be reviewed to identify new evidence specific
to people with CKD, as debate about optimal salt intake in the
general population is ongoing.59 The conference participants
questioned whether a level 1C recommendation is too strong
based on the current evidence.60,61
Therapeutic thresholds and targets of BP
In light of new research findings, especially from SPRINT,
each recommendation in the 2012 BP guideline regarding BP
diagnosis thresholds and treatment targets1 should be
considered for revision. Whether separate recommendations
are needed for diabetes mellitus and non-diabetes mellitus,
and for different levels of albuminuria, depends in large part
on where the threshold is set for lower-risk patients. For
example, if the threshold is SBP <120 mm Hg for all patients,
separate recommendations for higher-risk individuals would
not be needed.
The extent to which SPRINT findings can and should be
applied to persons with CKD G3b-G4 was debated.Kidney International (2019) 95, 1027–1036Impairment in the glomerular filtration rate (GFR) and
albuminuria levels in the CKD subgroup in SPRINT were
moderate (mean estimated GFR [eGFR] 48 ml/min per 1.73
m2; mean urinary albumin-to-creatinine ratio 81 mg/g). It is
unclear if the benefits and risks observed in SPRINT are
applicable to patients with more advanced CKD or those with
severely increased albuminuria, especially given that proteinuria
>1 g/d was an explicit exclusion criterion in SPRINT. Indeed, a
post hoc analysis of SPRINT suggested that the balance of risk
and benefit from intensive BP lowering depended on the severity
of CKD, with no apparent net benefit among patients with
eGFR <45 ml/min per 1.73 m2, a relatively small subgroup.62
There is biological basis for the potential unfavorable risk/
benefit ratio of intensive SBP lowering in advanced CKD. Those
patients frequently have increased arterial stiffness and increased
pulse pressure.63 Antihypertensive therapy could excessively
decrease DBP, thus compromising coronary blood flow,
although no RCT evidence of increased risks of myocardial
infarction or heart failure at lower BP targets has been identi-
fied.64,65 In fact, a recent post hoc analysis of SPRINT data
showed no evidence that the cardiovascular benefits of intensive
SBP lowering differed by baseline DBP, including the lowest
DBP quintile of 61  5 mm Hg.66 Conference participants
discussed whether limits of DBP for SBP reduction should be
lower but doubted that evidence was sufficient to support a
limit. Further, participants felt that the well-recognized phe-
nomenon of “J” curves obtained when plotting DBP against risk
of adverse outcomes was likely due to confounding by comor-
bidities. The literature needs to be critically reviewed before
revised guidelines on DBP targets in the CKD population can be
considered. Specific data on BP targets in advanced CKD (e.g.,
eGFR <45 ml/min per 1.73 m2) and those with severely
increased proteinuria are urgently needed.
Concerns that lowering BP in CKD G3a-G4 patients older
than 69 years might lead to frequent hypotensive episodes have
been discussed.67 The recent SPRINT data in older patients68
and a subgroup analysis of older patients with CKD69 in
SPRINT suggest, however, that intensive SBP lowering is
generally safe. Whether safety depends on the number of drugs
required to achieve the target SBP remains unclear.
A further area of controversy was the optimal BP target in
people with diabetes, particularly because SPRINT excluded
patients with diabetes. The ACCORD (Action to Control
Cardiovascular Risk in Diabetes) trial, which included pa-
tients with diabetes with SBP targets identical to those in
SPRINT, failed to demonstrate statistically significant benefits
in its primary cardiovascular outcome.70 The lack of clear
benefit in ACCORD might relate to its more complicated
factorial study design, which included an intensive glucose-
lowering intervention that increased the risk of death.71
Conversely, a recent systematic review of BP lowering in
people with diabetes in the general population72 found clear
cardiovascular benefit for BP lowering among individuals
with baseline SBP over 140 mm Hg, but not for those with
lower BP levels. The large amount of new data in this area
requires careful review.1029
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BP-lowering therapies
Albuminuria. Meta-analysis of data from clinical trials has
suggested that albuminuria is a valid surrogate endpoint for
end-stage kidney disease (ESKD) for certain types of kidney
disease.73 Conference participants agreed, however, that
whether maximizing therapy to reduce albuminuria in addition
to BP control, especially using agents that block the renin-
angiotensin-aldosterone system (RAAS), is safe or effective in
improving clinical outcomes is still unknown. The 2012 KDIGO
BP Guideline also proposed a lower BP target and the use of
RAAS inhibitors for people with albuminuria or proteinuria.
Reassessment of these recommendations should be undertaken.
GFR. Conference participants debated whether the
increased risk for acute declines in eGFR associated with
lower BP goals in ACCORD, SPS3, and SPRINT is clinically
important. A retrospective analysis of participants in the Af-
rican American Study of Kidney Disease and Hypertension
(AASK) and Modification of Diet in Renal Disease (MDRD)
studies has indicated that patients who had acute eGFR
declines $20% from baseline during intensive BP lowering
were at increased risk of progression to ESKD.74 On the other
hand, acute declines of up to 30% in eGFR upon the initiation
of RAAS inhibitors were deemed by some investigators to
portend long-term renal benefit. The conference participants
felt that statistical methodological issues complicate the
interpretation of such data. Critical review of the literature
and the statistical methodologies used in various studies are
necessary to determine if recommendations can be formu-
lated. Analyses from BP-lowering trials using active run-in
periods where changes in eGFR can be assessed pre-
randomization instead of post-randomization would be
particularly helpful in resolving this controversy.
Apart from the acute change in GFR upon BP lowering,
several recent BP outcome trials, such as ACCORD, SPRINT,
and SPS3, have also demonstrated that GFR loss is slightly but
consistently faster during chronic follow-up with a lower BP
target. These observations need to be carefully considered in
the revised BP guideline.
Choice of antihypertensive agents
The conference participants agreed that an angiotensin-
converting-enzyme inhibitor (ACEi) or angiotensin receptor
blocker (ARB) should be the agent of first choice among patients
with severely increased albuminuria (i.e., >300 mg/g [>30 mg/
mmol]) while some favor the preferential use of an ACEi or ARB
for all CKDpatientswith diabetes andhypertension. The evidence
favoring their preferential use for nondiabetic patients with CKD
and moderately increased albuminuria (i.e., <300 mg/g (<30
mg/mmol) is less persuasive. The relative benefits of these agents
compared with alternatives also depend on ethnic origin and the
healthcare setting (given the need to monitor for hyperkalemia).
Hyperkalemia
RAAS blockers inhibit renal potassium excretion and there-
fore increase the risk of hyperkalemia, particularly in patients1030with CKD, hence limiting their utilization despite their
proven benefits. In a large retrospective analysis from the
Veterans Health Administration database, CKD and RAAS
inhibitor prescriptions were the strongest predictors of
hyperkalemia.75 Several studies have shown a U-shaped
relationship between serum potassium level and risk of
death,75–79 although the risks may be lower if patients are
under the active care of a nephrologist.80 The odds ratio of
death from severe hyperkalemia (potassium >6.0 mmol/l)
within 1 day of a measurement of serum potassium was very
large, amounting to 31.6 for those without CKD, 19.5 for
those with CKD G3, 11.6 for those with CKD G4, and 8.0 for
those with CKD G5, suggesting the possibility of some degree
of systemic adaptation to hyperkalemia with kidney impair-
ment.75 However, the absolute risks of death associated with
hyperkalemia over an 18-month period were higher among
those with CKD, heart failure, and diabetes.76 In a cohort of
patients managed by nephrologists, however, hypokalemia
was associated with even higher risks of death than
hyperkalemia.77
Novel potassium-binding drugs, such as patiromer and
sodium zirconium cyclosilicate, could potentially change the
pharmacotherapy for hypertension, but conference partici-
pants felt it was too early to evaluate the role of these drugs in
routine clinical practice. Further research is needed to
examine whether potassium binders allow better treatment of
hypertension, for example, using RAAS blockers, and thus
reduce cardiovascular and renal complications (Table 2).
Dual inhibition of the renin-angiotensin system
Post hoc analyses from the ONgoing Telmisartan Alone and in
Combination with Ramipril Global Endpoint Trial (ONTAR-
GET) and data from the Aliskiren Trial in Type 2 Diabetes Using
Cardiorenal Endpoints (ALTITUDE) and the Veterans Affairs
Nephropathy in Diabetes (VA NEPHRON-D) trials suggested
that dual therapy with an ACEi, an ARB, and/or a direct renin
inhibitor did not provide cardiovascular or kidney benefit
compared with monotherapy in patients with low eGFR and
elevated albuminuria, although BP was somewhat lower.81
Additionally, the risks of hyperkalemia, acute kidney injury,
and hypotension were greater with dual regimens.82 In 2014, the
European Medicines Agency endorsed restrictions on combining
different classes of RAAS inhibitors in patients with diabetic
nephropathy. A more recent meta-analysis suggested that dual
ACEi and ARB treatments have efficacy in preventing ESKD in
adults with diabetic kidney disease, if the treatments can be
implemented safely.83 Conference participants discussed the
possibility that dual RAAS regimens have long-term benefits in
specific subgroups of patients, particularly those with a sub-
stantially lower degree of albuminuria while they are on dual
versus monotherapy of RAAS inhibitors or when dual blockers
are used in combination with potassium binders. Combining an
ACEi or ARB with mineralocorticoid receptor antagonist may
also confer additional protection, but the absence of informative
RCTs means that we cannot currently assess the relative risks
(including acute kidney injury and hyperkalemia) and benefits.Kidney International (2019) 95, 1027–1036
Table 2 | Research recommendations for BP management in
CKD
 Compare CKD G3a-G5 ND BP readings obtained using various BP
measurement techniques, including casual office BP, standardized
office BP, automated office BP, home BP and ambulatory BP
measurements in adult and pediatric populations
 Relate different BP measurement techniques to cardiovascular and
kidney outcomes in observational studies
 Investigate long-term clinical implications of acute lowering of
glomerular filtration rate with intensive BP control and/or with renin-
angiotensin-aldosterone system inhibitors
 Investigate whether oral potassium binders in CKD G3a-G5 ND with
hypertension allow for the use of renin-angiotensin-aldosterone
system inhibitors, and hence better treatment of hypertension and
improvement in cardiovascular and kidney outcomes
 Determine whether subgroups within CKD G3a-G5 ND benefit from
dual inhibition of the renin-angiotensin-aldosterone system in terms
of cardiovascular and kidney outcomes and favorable benefit-to-risk
ratio
 Determine the optimal management strategy for resistant hypertension
in CKD G3a-G5 ND
 Address management of hypertension in older patients with CKD G3a-
G5 ND, especially in terms of BP target, the role of nonpharmacological
therapies, choice of antihypertensive agents, life expectancy, and
bidirectional interactions between BP treatment and psychosocial
environment
 Conduct randomized trials to evaluate the effects of various BP targets
on cardiovascular and kidney outcomes in advanced CKD, diabetic CKD,
severely increased proteinuria CKD, and kidney transplant patients
 Determine thresholds for initiating treatment and for BP targets in
pediatric CKD patients
BP, blood pressure; CKD, chronic kidney disease; ND, nondialysis
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patient groups.
Resistant hypertension
Resistant hypertension is common in CKD. The conference
participants discussed the possible role of mineralocorticoid
receptor antagonists (e.g., spironolactone, epleronone) in the
treatment of resistant hypertension (by extension from
studies in the general population) and as add-on anti-pro-
teinuric treatment, with or without the concomitant use of
novel potassium-binding drugs. However, participants
concluded that evidence is insufficient to define the role of
these agents in practice for those with CKD.MANAGING BLOOD PRESSURE IN OLDER PATIENTS WITH CKD
The 2012 KDIGO BP guideline assigned a chapter to older
patients and noted that very little evidence is available to
guide management in nondiabetic older patients with CKD.
Conference participants agreed that, although the term “older
patients” has no universal definition, treatment decisions
should carefully take into account age, comorbidities, and
other concomitant therapies, and that dose escalation of
antihypertensive agents should be gradual, with close atten-
tion to adverse events.1 The BP treatment target for older
patients with advanced CKD is particularly controversial.
Given the increasing incidence of ESKD in the older hyper-
tensive population, study of the effects of antihypertensiveKidney International (2019) 95, 1027–1036therapy on cardiovascular and renal outcomes in older pa-
tients with advanced CKD remains an unmet need.
Initiating antihypertensive therapy and treatment targets in
older patients with CKD
Conference participants recognized that for nonambulatory
or nursing-home patient populations with CKD, no clinical
trial data are available to inform decisions about antihyper-
tensive therapy. Given that the aggregate benefits of antihy-
pertensive therapy do not appear until 1–2 years after
initiation of treatment, decisions regarding initiation of BP
therapy and goals of treatment in persons with otherwise
limited life expectancy should be based on shared decision-
making with patients, family members, and caregivers, tak-
ing other medical and social conditions into consideration.
Based on available data,2,68,69,84 conference participants
discussed whether the target for SBP should vary by age in
adult CKD patients. First, participants noted that most trials
in the older population have targeted SBP instead of DBP,
since SBP better predicts cardiovascular disease, and isolated
diastolic hypertension is rare in older adults. The SPRINT
trial did not capture the whole spectrum of CKD patients, as
patients with diabetes mellitus, eGFR <20 ml/min per 1.73
m2, or proteinuria >1 g/d were excluded.2 Nonetheless, re-
sults from the SPRINT study suggest that cardiovascular and
survival benefits are provided by an SBP target of <120
mm Hg (measured by automated oscillometric office BP) in
the CKD population, including in those over 75 years old.66
Intensive SBP lowering did not impair gait speed or self-
reported mobility.85 Less clear is whether older CKD pa-
tients with SBPs between 120 and 130 mm Hg (by stan-
dardized, not casual, BP measurement) should initiate
treatment. A systematic review and perhaps future trials were
suggested to provide insight into this issue. At the same time,
such a systematic review should summarize methods of BP
measurement in outcome trials.
Older patients commonly have CKD G3a without signifi-
cant albuminuria.69 Conference participants questioned
whether the degree of albuminuria should influence BP tar-
gets in this population for renoprotective effects, as discussed
above. Cardiovascular risk reduction should be a priority in
this group, but no evidence to date suggests that the
cardiovascular-protective effects of lowering BP depend on
the degree of albuminuria.86
Choice of antihypertensive agents in older patients with CKD
The use of ACEis, ARBs, diuretics, and calcium channel
blockers has been shown to be associated with improved
cardiovascular outcomes in CKD patients.87–89 The 2012
KDIGO BP Guideline recommended that, if the degree of
albuminuria is higher than 300 mg/g, ACEis or ARBs be
included in the antihypertensive regimen because of their
renoprotective effects. In a subgroup analysis of an RCT in
older hypertensive patients, cardiovascular events were more
frequent with single high-dose ARB therapy, compared with
combination therapies using an ARB plus a calcium channel1031
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conference participants suggested that this study be consid-
ered in the guideline update.
Treatment monitoring in older patients with CKD
With antihypertensive therapy, the concern is that older pa-
tients are likely to have a higher incidence of serious adverse
events than younger patients. However, among those aged 75
years or older, targeting SBP <120 mm Hg did not cause
more serious adverse events than targeting SBP <140 mm Hg
in the entire cohort68 or in the CKD subgroup69 in SPRINT.
Nonetheless, BP management in older individuals with CKD
should be individualized, taking into account comorbidities,
polypharmacy, and other factors.1
MANAGING BP AMONG INDIVIDUALS WITH CKD AND
PREVIOUS STROKE
This population is not specifically mentioned in the 2012
KDIGO BP guideline. The risk of stroke increases additively
with declining GFR and increasing albuminuria, particularly
in patients with an eGFR below 60 ml/min per 1.73 m2,91 and
lowering BP generally reduces the risk for stroke and other
cardiovascular events.92 Currently, no evidence suggests that a
history of prior stroke should change the chronic treatment of
BP in patients with CKD, as shown in a subgroup analysis of
the Perindopril Protection against Recurrent Stroke Study
(PROGRESS),93 although data are limited. In SPRINT, a
history of stroke was an exclusion criterion. The SPS3 study94
targeted SBP treatment to <130 mm Hg in patients with a
history of prior stroke and included 474 patients with baseline
eGFR <60 ml/min per 1.73 m2. Compared with an SBP target
of 130–149 mm Hg, a statistically nonsignificant reduction in
the cardiovascular composite outcome occurred in the
intensive SBP arm, with no effect modification by the baseline
eGFR. Because of the paucity of data in this area, it is hoped
that future RCTs of BP targets in people with prior stroke will
include substantial numbers of individuals with CKD.95 Sys-
tematic reviews, meta-analyses, and perhaps additional data
from RCTs are needed to inform the best practices for
managing BP in CKD patients acutely and chronically after a
stroke. At present, formulating recommendations for this
group of patients would be difficult.
MANAGING BP IN KIDNEY TRANSPLANT POPULATIONS
Treatment thresholds and targets in transplant recipients
The KDIGO 2012 BP guideline suggested that adult kidney
transplant recipients who have an office SBP consistently
>130 mm Hg or a DBP consistently >80 mm Hg be treated
to maintain SBP <130 mm Hg and DBP <80 mm Hg,
irrespective of the level of albuminuria,1 largely because the
work group believed that adult transplant recipients are at
high risk for both graft loss and development of cardiovas-
cular disease. Since 2012, evidence published from a post hoc
analysis in the FAVORIT (Folic Acid for Vascular Outcome
Reduction in Transplantation) Trial showed that SBP in-
creases were associated with increased risk for cardiovascular1032disease in kidney transplant recipients.96 This study did not
address BP thresholds related to allograft failure. An impor-
tant point to note is that BP was not a randomized inter-
vention in FAVORIT. An earlier analysis of the Collaborative
Transplant Study97 demonstrated a close association of SBP
and chronic allograft failure in a monotonic manner in the
range of SBP down to 140 mm Hg and DBP down to 90
mm Hg. No RCTs have been conducted that could inform the
optimal target BP with regard to cardiovascular or renal
allograft outcomes in kidney transplant recipients.
A key issue is whether evidence regarding management of
BP in nontransplant CKD patients can be extrapolated to
transplant recipients. Conference participants felt that such
extrapolation should be tempered because transplanted kid-
neys are denervated and therefore may not autoregulate
glomerular perfusion in the same manner as nontransplanted
kidneys. Further, kidney transplant recipients are at risk of
transplant renal artery stenosis, and they are frequently pre-
scribed calcineurin inhibitors, which raise BP and influence
renal perfusion. Based on clinical experiences, concerns were
expressed regarding targeting SBP to <120 mm Hg in
transplant recipients. Adequately powered outcome trials in
kidney transplant patients, with a design similar to that of
SPRINT, are needed, but obtaining the required financial
resources for such a trial will be challenging.
Choice of antihypertensive agents in transplant recipients
The 2012 KDIGO BP guideline did not specify preferred
choices of antihypertensive agents.1 Since 2012, reports have
compared antihypertensive drugs in kidney transplant re-
cipients. A 2016 meta-analysis by Hiremath et al.98 suggested
that ACEis or ARBs did not alter all-cause mortality or kidney
outcomes but did increase the risk for hyperkalemia. Because
of the small number of events and relatively short follow-up
durations, the results of the meta-analysis were inconclusive.
In a randomized crossover trial of chlorthalidone versus
amlodipine among kidney transplant patients treated with
tacrolimus, patients in both arms experienced similar reductions
in ambulatory SBP after 8 weeks.99 Chlorthalidone reduced
proteinuria by 30% but also temporarily reduced kidney func-
tion. In an RCTof 153 kidney transplant recipients, participants
were randomized to losartan versus matched placebo for up to 5
years. Both arms had their BP treated to a goal of <130/80
mm Hg using other agents. Randomization to losartan did not
have a significant influence on the time to a composite of ESKD,
death, or doubling of creatinine level.100
Conference participants felt that this new evidence should
be considered in the guideline update. The existing Recom-
mendation 5.2 suggesting that choice of antihypertensive
therapy take into account the time after transplantation, use
of calcineurin inhibitors, presence or absence of albuminuria,
and other comorbid conditions remains appropriate.
Living kidney donors
Living kidney donors were not specifically mentioned in the
2012 KDIGO BP guideline. In these individuals, each year ofKidney International (2019) 95, 1027–1036
AK Cheung et al.: Blood pressure in kidney disease: A KDIGO conference report KD IGO execu t i ve conc lu s i onsage is associated with 9% greater odds of high BP requiring
medication.101 The KDIGO 2017 clinical practice guideline
on living kidney donors suggests that donor candidates be
informed that donation may accelerate a rise in BP and that
they should have BP measured every year postdonation.102
Conference participants agreed that although data linking
close monitoring to improved clinical outcomes are not
available, these recommendations are appropriate.
MANAGING BP IN PEDIATRIC CKD POPULATIONS
Thresholds for initiating treatment
Clinical trials assessing the effects of different BP targets on
hard clinical endpoints in children who have CKD are limited.
Applying BP guidelines in adults who have CKD to children
who have CKD is not advisable because the normative BP
values in children are dependent on age, gender, and height.
For the general pediatric population, the threshold for
initiation of antihypertensive therapy has been the 95th
percentile of normative BP values in the general pediatric
population. Since the prior KDIGO CKD BP guideline was
published, however, recognition of the effects of obesity on
BP in children in general has increased. Thus, the American
Academy of Pediatrics (AAP) guideline recently revised
normative pediatric BP tables based on normal-weight chil-
dren.103 The AAP further recommends that children and
adolescents with CKD be evaluated for hypertension using
automated oscillometric equipment to measure BP in an
office-based setting.103 However, published normative BP
values in children so far refer only to office auscultatory
measurements. More normative data in children are needed
for office-based and home-based automated oscillometric BP
and ambulatory BP. Some normative data are available for
ambulatory BP, but only in Western European populations.104
Recommendation 6.1 in the 2012 KDIGO BP guideline
suggested that for children with CKD, treatment should be
started when BP is consistently above the 90th percentile for a
child’s age, sex, and height.1 This recommendation is
consistent with guidance from Hypertension Canada105 but at
odds with that of the AAP103 and the European Society of
Hypertension,106 which recommend that treatment be initi-
ated if BP is consistently above the 95th percentile in the
general pediatric population. A point to note is that these 3
guidelines are not specific to CKD patients. The AAP 2017
also recommends initiating treatment if BP is >130/80
mm Hg for children ages 13 years and above.103 However, the
cutoff age of 13 years in CKD patients was considered
potentially problematic by conference participants because
many pediatric patients with CKD have small stature and may
have a lower BP than is typical for their age. The 2012 KDIGO
BP guideline for pediatric CKD patients should be recon-
sidered in light of these new AAP normative data and other
guidelines.
Treatment targets
Recommendation 6.2 in the 2012 KDIGO BP guideline sug-
gests that SBP and DBP be lowered to values #50th percentileKidney International (2019) 95, 1027–1036in children with CKD, particularly in those with proteinuria.1
This recommendation was based primarily on the Effect of
Strict Blood Pressure Control and ACE-Inhibition on Pro-
gression of Chronic Renal Failure in Pediatric Patients
(ESCAPE) trial, in which hypertensive pediatric CKD patients
randomized to a mean arterial BP target of <50th percentile
of normative values based on ambulatory BP measurements
had fewer renal events than those randomized to the 50th–
95th percentile.107 Yet, the KDIGO recommendation has
applied these targets to SBP and DBP measured using the
auscultatory method. Therefore, conference participants felt
that the 2012 KDIGO guideline should be revised accordingly.
On the other hand, the fact that ambulatory BP monitoring
may not be widely available was noted; therefore, guidance
also should provide a target clinic BP using automated
oscillometric devices as an alternative. Provision of this
guidance would require new normative data on automated
oscillometric office-based BP readings that correspond to
specific ambulatory BP levels for any given age, sex, and
height. Development of such data was felt to be an important
research recommendation.
Choice of antihypertensive agent
The 2012 KDIGO guideline Recommendation 6.3 suggests
that an ARB or ACEi be used in children with CKD in whom
treatment with BP-lowering drugs is indicated, irrespective of
the level of proteinuria.1 This recommendation was based
largely on preclinical data and data from adult studies. Only 4
small uncontrolled trials have shown that ACEis or ARBs
reduce proteinuria in children with CKD.107 Evidence in-
dicates that losartan108 and enalapril109 each lowers protein-
uria in children, and that their effects are comparable,110 but
data on end-organ consequences are unavailable. Conference
participants also questioned whether the presence of pro-
teinuria should be a consideration for the preferential use of
ARBs or ACEis over other agents. Further research is needed
on the long-term safety and efficacy of ARBs and ACEis in
children with CKD.
Pediatric kidney transplant recipients
BP management in pediatric transplant recipients was
considered to be an area without a sufficient evidence base to
support guidelines. Additional research is warranted.
CONCLUSION
Overall, conference participants agreed that an update of
the 2012 KDIGO BP guideline would be timely, particularly
given the SPRINT data. In particular, BP thresholds and
targets for treatment need to be reconsidered. Recom-
mendations on where and how BP should be measured
need to be emphasized. RCT data on the cardiovascular and
survival benefits of diabetic kidney disease, advanced CKD,
and severely increased proteinuric CKD are urgently
needed for guidance regarding BP management in these
CKD subgroups. Implementation of the updated guidelines
was also recognized to be important, a process that1033
KDIGO execu t i ve conc lu s i ons AK Cheung et al.: Blood pressure in kidney disease: A KDIGO conference reportpotentially can be facilitated by development of a patient
decision aid for initiating antihypertensive treatment, with
estimates of absolute risk and risk reduction from the
treatment.APPENDIX
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